| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 05/24/2023 | RAPT Therapeutics, Inc. | RAPT | Grant | Stock Option (right to buy) | 12.9k | $20.93 | $270.8k | | 05/24/2023 |
| 05/10/2023 | NGM BIOPHARMACEUTICALS INC | NGM | Grant | Stock Option (Right to Buy) | 78.4k | $3.69 | $289.3k | | 05/10/2023 |
| 06/08/2022 | Lyell Immunopharma, Inc. | LYEL | Grant | Option (right to buy) | 65k | $5.31 | $345.2k | | 06/08/2022 |
| 05/25/2022 | RAPT Therapeutics, Inc. | RAPT | Grant | Stock Option (right to buy) | 8.5k | $13.64 | $115.9k | | 05/25/2022 |
| 03/31/2022 | RAPT Therapeutics, Inc. | RAPT | Grant | Stock Option (right to buy) | 5.2k | $21.99 | $114.5k | | 03/31/2022 |
| 03/03/2022 | NGM BIOPHARMACEUTICALS INC | NGM | Grant | Stock Option (Right to Buy) | 80k | $15.20 | $1.2M | | 03/03/2022 |
| 05/28/2021 | RAPT Therapeutics, Inc. | RAPT | Grant | Stock Option (right to buy) | 7.5k | $19.30 | $144.8k | | 05/28/2021 |
| 03/17/2021 | NGM BIOPHARMACEUTICALS INC | NGM | Grant | Stock Option (Right to Buy) | 80k | $31.93 | $2.6M | | 03/17/2021 |
| 11/19/2020 | RAPT Therapeutics, Inc. | RAPT | Purchase | Common Stock | 10k | $16.22 | $162.2k | | 11/19/2020 |
| 06/18/2020 | RAPT Therapeutics, Inc. | RAPT | Grant | Stock Option (right to buy) | 7.5k | $28.27 | $212k | | 06/18/2020 |
| 02/04/2020 | NGM BIOPHARMACEUTICALS INC | NGM | Grant | Stock Option (Right to Buy) | 75k | $16.47 | $1.2M | | 02/04/2020 |
| 11/04/2019 | RAPT Therapeutics, Inc. | RAPT | Conversion | Series B Preferred Stock | 100k | $0.00 | $0 | By Rieflin Family Trust u/a dtd 4/3/00, William J. Rieflin and Prudence H. Rieflin, Trustees | 11/04/2019 |
| 11/04/2019 | RAPT Therapeutics, Inc. | RAPT | Purchase | Common Stock | 8k | $12.00 | $96k | | 11/04/2019 |
| 11/04/2019 | RAPT Therapeutics, Inc. | RAPT | Conversion | Series A Preferred Stock | 260.3k | $0.00 | $0 | By Rieflin Family Trust u/a dtd 4/3/00, William J. Rieflin and Prudence H. Rieflin, Trustees | 11/04/2019 |
| 11/04/2019 | RAPT Therapeutics, Inc. | RAPT | Conversion | Common Stock | 43.4k | $0.00 | $0 | By Rieflin Family Trust u/a dtd 4/3/00, William J. Rieflin and Prudence H. Rieflin, Trustees | 11/04/2019 |
| 11/04/2019 | RAPT Therapeutics, Inc. | RAPT | Conversion | Common Stock | 16.7k | $0.00 | $0 | By Rieflin Family Trust u/a dtd 4/3/00, William J. Rieflin and Prudence H. Rieflin, Trustees | 11/04/2019 |
| 10/30/2019 | RAPT Therapeutics, Inc. | RAPT | Grant | Stock Option (right to buy) | 15.3k | $12.00 | $184k | | 10/30/2019 |
| 10/30/2019 | RAPT Therapeutics, Inc. | RAPT | Grant | Stock Option (right to buy) | 3.3k | $12.00 | $40k | | 10/30/2019 |
| 04/08/2019 | NGM BIOPHARMACEUTICALS INC | NGM | Conversion | Series A Preferred Stock | 50k | $0.00 | $0 | See Footnote | 04/08/2019 |
| 04/08/2019 | NGM BIOPHARMACEUTICALS INC | NGM | Conversion | Series B Preferred Stock | 6.7k | $0.00 | $0 | See Footnote | 04/08/2019 |
| 04/08/2019 | NGM BIOPHARMACEUTICALS INC | NGM | Conversion | Common Stock | 56.7k | $0.00 | $0 | See Footnotes | 04/08/2019 |
| 05/16/2012 | XENOPORT INC | XNPT | Grant | Non-employee director stock unit | 5k | $0.00 | $0 | | 05/16/2012 |
| 05/16/2012 | XENOPORT INC | XNPT | Grant | Non-employee director stock option | 15k | $6.18 | $92.7k | | 05/16/2012 |
| 12/16/2011 | XENOPORT INC | XNPT | Purchase | Common Stock | 10k | $3.86 | $38.6k | By Trust | 12/16/2011 |
| 05/13/2010 | XENOPORT INC | XNPT | Grant | Performance stock unit | 40k | $0.00 | $0 | | 05/13/2010 |
| 03/12/2010 | XENOPORT INC | XNPT | Grant | Restricted stock unit | 40k | $0.00 | $0 | | 03/12/2010 |
| 02/01/2010 | XENOPORT INC | XNPT | Exercise | Restricted stock unit | 1.2k | $0.00 | $0 | | 02/01/2010 |